Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT
MARKETING AUTHORIZATION APPLICATION FOR LECANKITUG INJECTION ACCEPTED FOR REVIEW BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Recently, Livzon MABPharm Inc.*(珠海市麗珠單抗生物技術有限公司) ("**Livzon MAB**"), a controlling subsidiary of Livzon Pharmaceutical Group Inc.*(麗珠醫藥集團股份有限公司) (the "**Company**"), received the Acceptance Notice (Acceptance No. CXSS2600087) approved and issued by the National Medical Products Administration* (國家藥品監督管理局) ("**NMPA**"). The marketing authorization application for the domestically produced drug, Lecankitug Injection (萊康奇塔單抗注射液)(the "**Drug**") jointly developed by Livzon MAB and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.*(北京鑫康合生物醫藥科技有限公司)("**Beijing Xinkanghe**") has been formally accepted by the NMPA. Relevant details are announced as follows:

BASIC INFORMATION ABOUT THE DRUG

Drug name: 萊康奇塔單抗注射液

English/Latin name: Lecankitug Injection

Dosage form: Injection

Specification: 160mg (1.6mL) / vial

Application item: Marketing authorization application for domestically produced drug

Registration classification: Class 1 therapeutic biological product

Applicant: Livzon MAB

Proposed indication (or main treatments):for adult patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis) with inadequate response or intolerance to conventional therapy. Approval conclusion of the Acceptance Notice:In accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China* (《中華人民共和國行政許 可法》), after review, it is decided to accept the application.

DRUG DEVELOPMENT AND RELATED CONDITIONS

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic and immune-mediated disease, with an estimated patient population of approximately 4 million in China. The IL-17 pathway has emerged as an important therapeutic target in this disease area. The New Drug Application ("**NDA**") of Lecankitug Injection for the treatment of ankylosing spondylitis has been formally accepted by the NMPA. This marks the second accepted indication application for the Drug, following the acceptance and inclusion in the Priority Review pathway of its psoriasis indication application. The NDA is supported by a pivotal Phase III registrational clinical study, which is a multi-center, randomized, double-blind, placebo-controlled trial. The study results demonstrate that the Drug exhibits definite and robust efficacy with multiple advantages: rapid onset of action, with between-group differences observed as early as Week 1, enabling quick improvement of patients' inflammatory markers; significantly higher clinical response rates at Week 16 compared with the placebo group, achieving deep symptomatic relief; sustained and stable efficacy up to Week 52, with clear benefits also observed in patients switching to the Drug, alongside improvements in patients' quality of life. The Drug is administered via subcutaneous injection every 4 weeks, offering convenient dosing that helps improve treatment adherence. The Drug has demonstrated good safety and tolerability, with adverse event rates comparable to the placebo group and no new safety signals identified. Additionally, the Drug is applicable to both TNF inhibitor (TNFi)-naïve and TNFi-experienced populations, delivering stable and consistent therapeutic benefits regardless of patients' prior TNFi treatment history.

The Drug is jointly developed by Livzon MAB and Beijing Xinkanghe.

As at the date of this announcement, the cumulative direct investment in research and development expenses for Lecankitug Injection amounts to approximately RMB216.9 million.

MARKET CONDITION OF THE DRUG

According to the databases on the official websites of the NMPA and the Center for Drug Evaluation, as at the date of this announcement, with regard to the IL-17A/F dual target, only one imported product (bimekizumab) has been approved for the indication of ankylosing spondylitis in mainland China, and no domestically-developed product has yet obtained approval for such indication.

IMPACT ON THE COMPANY AND RISK WARNING

In accordance with the requirements of relevant laws and regulations on national drug registration, after being accepted by the NMPA, the Marketing Authorization Application for the Drug will enter the review and approval procedure conducted by the CDE. The timeline for completion and the final approval outcome are subject to uncertainties. The receipt of the Acceptance Notice for the Product will not have material impact on the Company's financial results in the near term. The Company will perform its information disclosure obligations in a timely manner in accordance with the progress of the registration application. Investors are advised to exercise caution in making investment decisions and pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
1 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* *For identification purpose only*